Last reviewed · How we verify
VSV-IFNβ-NIS
At a glance
| Generic name | VSV-IFNβ-NIS |
|---|---|
| Also known as | Voyager-V1, VSV, VSV2 |
| Sponsor | Vyriad, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma (PHASE1)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (PHASE1, PHASE2)
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (PHASE2)
- Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VSV-IFNβ-NIS CI brief — competitive landscape report
- VSV-IFNβ-NIS updates RSS · CI watch RSS
- Vyriad, Inc. portfolio CI